menu
    • menu
    [{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IRX4204","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IRX4204","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Io Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"IRX4204","moa":"RXR nuclear receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Io Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Io Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Io Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for IRX4204

    Menu

    IRX4204

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Io Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Io Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigational MS Drug Restores Mobility in Mice

                            Details : IRX4204 is a RXR agonist, small molecule drug candidate, which is currently being evaluated for the treatment of patients with multiple sclerosis.

                            Product Name : IRX4204

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 02, 2025

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IO Biotech

                            Denmark arrow
                            RNA Therapeutics
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Io Therapeutics Presents IRX4204 Results for ALS Treatment

                            Details : IRX4204 is the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS).

                            Product Name : IRX4204

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 16, 2024

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IO Biotech

                            Denmark arrow
                            BIO CEO & Investor
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Io Therapeutics Presents IRX4204 Data for Aging, Parkinson’s, and Alzheimer’s

                            Details : IRX4204 is a highly potent and highly selective, orally available, third generation RXR agonist compound which IS being tested in early phase clinical trials in patients with Parkinson’s disease

                            Product Name : IRX4204

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 09, 2024

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth